Oligonucleotide Synthesis Market by Offering [Synthesis Products (Consumables, Equipment), Synthesized Oligos (DNA, RNA), Oligo-based Drugs (ASO, siRNA), Therapy Area [Rare Diseases, Neurology, Oncology], Competition - Global Forecast to 2031
The oligonucleotide synthesis market is projected to reach USD 32.72 billion by 2031, up from USD 14.64 billion in 2026, at a CAGR of 17.4% over the forecast period. Market growth is driven by several factors, including increasing demand for synthesized oligonucleotides such as primers and probes for research and diagnostic applications. Rising technological advancements in oligonucleotide synthesis are also expected to contribute to market growth during the forecast period.
By offering, the oligonucleotide-based drugs segment accounted for the largest share of the market in 2025.
The market is segmented into oligonucleotide-based drugs, synthesized oligonucleotides and oligonucleotide synthesis products (consumables and equipment). In 2025, the oligonucleotide-based drugs segment accounted for the largest share of the market. This large share reflects growing acceptance of these treatments and their proven success, especially for rare and hereditary diseases. Medications such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) target disease-causing genes, providing precise and personalized treatments. This growing demand is fueled by advancements in RNA-targeted therapies and delivery systems, the rising prevalence of genetic diseases, and significant investments in research and development of RNA-based treatments.
In 2025, North America accounted for the largest share of the overall oligonucleotide synthesis market.
The US is the largest market for oligonucleotide synthesis, driving North America's commanding share of global market revenue. This dominance is propelled by a dense ecosystem of major biopharmaceutical companies, world-class academic research institutes, and extensive venture capital investment in genomic innovation. Furthermore, a massive clinical drug pipeline featuring over 150 oligo-based therapeutics, coupled with clear, supportive regulatory frameworks from the US FDA, drives demand for complex, large-scale, high-purity GMP production at a level unmatched by any other nation.
The primary interviews conducted for this report can be categorized as follows:
Biogen (US) Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), AstraZeneca (UK), Astellas Pharma Inc. (Japan), Jazz Pharmaceuticals Plc (Ireland), Nippon Shinyaku, Co. Ltd. (Japan), Ionis Pharmaceuticals, Inc. (US), and Novartis AG (Switzerland) are some of the key companies offering oligonucleotide-based drugs, profiled in the report.
Research Coverage:
This research report categorizes oligonucleotide synthesis market by offering (oligonucleotide-based drugs, synthesized oligonucleotides, oligonucleotide synthesis products); oligonucleotide-based drugs (by type: antisense oligonucleotide-based drugs, siRNA oligonucleotide-based drugs, other oligonucleotide-based drugs; by therapeutic area: rare diseases, cardiometabolic diseases, neurology, other therapeutic areas; by end user: hospitals, specialty clinics, home care settings, other end users); synthesized oligonucleotides (by oligo type: primers, probes, DNA oligos, RNA oligos, other oligos; by application: therapeutic applications, research applications, and diagnostic applications, by end user: biopharmaceutical & biotechnology companies, CROs & CDMOs, academic & research institutes, and diagnostic companies & laboratories); oligonucleotide synthesis products (by type: consumables, oligo synthesis equipment; by application: therapeutic applications, research applications, and diagnostic applications, by end user: biopharmaceutical & biotechnology companies, CROs & CDMOs, academic & research institutes, and diagnostic companies & laboratories), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).
The report's scope covers detailed information on the primary factors, such as drivers, restraints, challenges, and opportunities, that influence the growth of the oligonucleotide synthesis market. A thorough analysis of key industry players has been conducted to provide insights into their business overviews, product offerings, key strategies, new product launches, acquisitions, and recent developments associated with the oligonucleotide synthesis market. This report also covers the competitive analysis of upcoming startups in the oligonucleotide synthesis market ecosystem.
Key Benefits of Buying the Report:
The report will help market leaders and new entrants by providing the closest approximations of revenue for the oligonucleotide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their business and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on key market drivers, restraints, challenges, trends, and opportunities.
The report provides insights on the following:
By offering, the oligonucleotide-based drugs segment accounted for the largest share of the market in 2025.
The market is segmented into oligonucleotide-based drugs, synthesized oligonucleotides and oligonucleotide synthesis products (consumables and equipment). In 2025, the oligonucleotide-based drugs segment accounted for the largest share of the market. This large share reflects growing acceptance of these treatments and their proven success, especially for rare and hereditary diseases. Medications such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) target disease-causing genes, providing precise and personalized treatments. This growing demand is fueled by advancements in RNA-targeted therapies and delivery systems, the rising prevalence of genetic diseases, and significant investments in research and development of RNA-based treatments.
In 2025, North America accounted for the largest share of the overall oligonucleotide synthesis market.
The US is the largest market for oligonucleotide synthesis, driving North America's commanding share of global market revenue. This dominance is propelled by a dense ecosystem of major biopharmaceutical companies, world-class academic research institutes, and extensive venture capital investment in genomic innovation. Furthermore, a massive clinical drug pipeline featuring over 150 oligo-based therapeutics, coupled with clear, supportive regulatory frameworks from the US FDA, drives demand for complex, large-scale, high-purity GMP production at a level unmatched by any other nation.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
- By Designation: C-level Executives - 30%, Directors- 45%, and Others- 25%
- By Region: North America - 35%, Europe - 25%, Asia Pacific - 15%, Latin America - 10%, Middle East- 10%, and Africa - 5%
Biogen (US) Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), AstraZeneca (UK), Astellas Pharma Inc. (Japan), Jazz Pharmaceuticals Plc (Ireland), Nippon Shinyaku, Co. Ltd. (Japan), Ionis Pharmaceuticals, Inc. (US), and Novartis AG (Switzerland) are some of the key companies offering oligonucleotide-based drugs, profiled in the report.
Research Coverage:
This research report categorizes oligonucleotide synthesis market by offering (oligonucleotide-based drugs, synthesized oligonucleotides, oligonucleotide synthesis products); oligonucleotide-based drugs (by type: antisense oligonucleotide-based drugs, siRNA oligonucleotide-based drugs, other oligonucleotide-based drugs; by therapeutic area: rare diseases, cardiometabolic diseases, neurology, other therapeutic areas; by end user: hospitals, specialty clinics, home care settings, other end users); synthesized oligonucleotides (by oligo type: primers, probes, DNA oligos, RNA oligos, other oligos; by application: therapeutic applications, research applications, and diagnostic applications, by end user: biopharmaceutical & biotechnology companies, CROs & CDMOs, academic & research institutes, and diagnostic companies & laboratories); oligonucleotide synthesis products (by type: consumables, oligo synthesis equipment; by application: therapeutic applications, research applications, and diagnostic applications, by end user: biopharmaceutical & biotechnology companies, CROs & CDMOs, academic & research institutes, and diagnostic companies & laboratories), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).
The report's scope covers detailed information on the primary factors, such as drivers, restraints, challenges, and opportunities, that influence the growth of the oligonucleotide synthesis market. A thorough analysis of key industry players has been conducted to provide insights into their business overviews, product offerings, key strategies, new product launches, acquisitions, and recent developments associated with the oligonucleotide synthesis market. This report also covers the competitive analysis of upcoming startups in the oligonucleotide synthesis market ecosystem.
Key Benefits of Buying the Report:
The report will help market leaders and new entrants by providing the closest approximations of revenue for the oligonucleotide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their business and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on key market drivers, restraints, challenges, trends, and opportunities.
The report provides insights on the following:
- Analysis of key drivers (Increasing use of synthesized oligos in therapeutic and diagnostic applications, technological advancements in oligonucleotide synthesis, growing government investments in life science research & synthetic biology, and growing focus on personalized medicine), restraints (Complexities associated with oligonucleotide-based drugs), opportunities (Increasing R&D investments by key players in emerging economies), and challenges (Lack of standard regulations, challenges in targeted delivery of oligonucleotides) are influencing the growth of the oligonucleotide synthesis market.
- Product Approvals: Detailed insights on newly approved products of the oligonucleotide synthesis market
- Market Development: Comprehensive information about lucrative markets – the report analyzes the oligonucleotide synthesis market across varied regions
- Market Diversification: Exhaustive information about new products, recent developments, and investments in the oligonucleotide synthesis market
- Pipeline Analysis: Comprehensive information about oligonucleotide-based drugs under clinical trials
- Competitive Assessment: In-depth assessment of market, growth strategies, and product offerings of leading players, including Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), and Merck KGaA (Germany), among others, offering oligonucleotide synthesis products and synthesized oligonucleotides. Biogen (US), Alnylam Pharmaceuticals, Inc. (US), Novartis AG (Switzerland), and Sarepta Therapeutics, Inc. (US) are key players in the oligonucleotide-based drugs segment of this market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONS COVERED
1.3.2 REGIONS COVERED
1.3.3 INCLUSIONS & EXCLUSIONS
1.3.4 YEARS CONSIDERED
1.3.5 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN OLIGONUCLEOTIDE SYNTHESIS MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
3.2 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING AND COUNTRY, 2025
3.3 OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
3.4 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY OFFERING, 2026 VS. 2031 (%)
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Rising commercialization and regulatory approvals of oligonucleotide therapeutics
4.2.1.2 Expanding RNA therapeutics pipeline and adoption of chemically modified oligos
4.2.1.3 Growing use of PCR, qPCR, NGS, CRISPR, synthetic biology, and molecular diagnostics
4.2.1.4 Increasing outsourcing of oligonucleotide synthesis and GMP manufacturing to CROs/CDMOs
4.2.2 RESTRAINTS
4.2.2.1 Complexity of large-scale oligonucleotide manufacturing and analytical control
4.2.3 OPPORTUNITIES
4.2.3.1 Increasing government and industry investments in life sciences, RNA therapeutics, and manufacturing infrastructure
4.2.3.2 Expansion of oligonucleotide therapeutics into cardiometabolic and common chronic diseases
4.2.3.3 Growth of companion diagnostics and precision medicine
4.2.4 CHALLENGES
4.2.4.1 Lack of standard regulations
4.2.4.2 Delivery of oligonucleotide drugs to specific targets
4.2.4.3 Sustainability & waste management in phosphoramidite-based synthesis
4.3 UNMET NEEDS & WHITE SPACES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
4.5.1 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS IN THE OLIGONUCLEOTIDE-BASED DRUGS MARKET
4.5.2 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS IN OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 OLIGONUCLEOTIDE-BASED DRUGS
5.1.1.1 Threat of new entrants
5.1.1.2 Threat of substitutes
5.1.1.3 Bargaining power of buyers
5.1.1.4 Bargaining power of suppliers
5.1.1.5 Intensity of competitive rivalry
5.1.2 SYNTHESIZED OLIGONUCLEOTIDES & OLIGONUCLEOTIDE SYNTHESIS PRODUCTS
5.1.2.1 Threat of new entrants
5.1.2.2 Threat of substitutes
5.1.2.3 Bargaining power of buyers
5.1.2.4 Bargaining power of suppliers
5.1.2.5 Intensity of competitive rivalry
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS & FORECAST
5.2.3 TRENDS IN GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY KEY PLAYER, 2022–2025
5.5.2 AVERAGE SELLING PRICE OF EQUIPMENT, BY REGION, 2025
5.6 KEY CONFERENCES & EVENTS, 2026–2027
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.8 INVESTMENT & FUNDING ACTIVITY
5.9 IMPACT OF 2025 US TARIFFS ON OLIGONUCLEOTIDE SYNTHESIS MARKET
5.9.1 INTRODUCTION
5.9.2 KEY TARIFF RATES
5.9.3 PRICE IMPACT ANALYSIS
5.9.4 IMPACT ON COUNTRY/REGION
5.9.4.1 North America
5.9.4.2 Europe
5.9.4.3 Asia Pacific
5.9.5 IMPACT ON END-USE INDUSTRIES
5.9.5.1 Hospitals
5.9.5.2 Specialty clinics
5.9.5.3 Home care settings & other end users
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 TECHNOLOGY ANALYSIS
6.1.1 KEY TECHNOLOGIES
6.1.1.1 Solid-phase phosphoramidite synthesis and scale-up
6.1.1.2 Liquid-phase synthesis
6.1.1.3 Chemical modification & backbone engineering
6.1.1.4 Conjugation & targeted delivery chemistry
6.1.1.5 Enzymatic & novel synthesis technologies
6.1.1.6 High-throughput automated oligonucleotide synthesis
6.1.1.7 Purification & analytical characterization
6.1.2 ADJACENT TECHNOLOGIES
6.1.2.1 Molecular biology & genomic technologies
6.1.2.2 Synthetic biology & gene synthesis
6.1.3 COMPLEMENTARY TECHNOLOGIES
6.1.3.1 Advanced oligonucleotide delivery technologies
6.1.3.2 AI-assisted oligonucleotide design
6.2 TECHNOLOGY/PRODUCT ROADMAP
6.3 FUTURE APPLICATIONS
6.4 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE SYNTHESIS MARKET
6.4.1 TOP USE CASES & MARKET POTENTIAL
6.4.2 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
6.4.3 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN OLIGONUCLEOTIDE SYNTHESIS MARKET
6.5 PATENT ANALYSIS & INNOVATIONS
6.5.1 OLIGONUCLEOTIDE SYNTHESIS MARKET: PATENT ANALYSIS, 2015–2025
6.5.2 KEY INNOVATIONS
7 SUSTAINABILITY & REGULATORY LANDSCAPE
7.1 REGIONAL REGULATIONS & COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 REGULATORY FRAMEWORK & REIMBURSEMENT
7.1.2.1 North America
7.1.2.2 Europe
7.1.2.3 Asia Pacific
7.1.2.4 Rest of the World
7.1.3 INDUSTRY STANDARDS
7.2 REIMBURSEMENT SCENARIO
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 KEY BUYING CRITERIA, BY END USER
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM END USERS
8.5 MARKET PROFITABILITY
9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING
9.1 INTRODUCTION
9.2 OLIGONUCLEOTIDE-BASED DRUGS
9.2.1 RECURRING CONSUMABLES DEMAND, AUTOMATION UPGRADES, AND ADVANCED SCREENING PLATFORMS TO DRIVE GROWTH
9.3 SYNTHESIZED OLIGONUCLEOTIDES
9.3.1 GROWING ADOPTION OF PCR, QPCR, NGS, AND CRISPR-BASED GENOME EDITING TO GENERATE SUBSTANTIAL DEMAND FOR CUSTOM PRIMERS
9.4 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS
9.4.1 INCREASING INSTALLATION OF AUTOMATED OLIGONUCLEOTIDE SYNTHESIZERS TO SUPPORT MARKET GROWTH
10 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE
10.1 INTRODUCTION
10.2 ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS
10.2.1 ASO-BASED DRUGS ACCOUNTED FOR LARGEST MARKET SHARE DUE TO THEIR ESTABLISHED CLINICAL SUCCESS ACROSS RARE AND NEUROLOGICAL DISEASES
10.3 SIRNA OLIGONUCLEOTIDE-BASED DRUGS
10.3.1 EXPANDING COMMERCIAL ADOPTION AND STRONG LATE-STAGE PIPELINES TO DRIVE GROWTH
10.4 OTHER OLIGONUCLEOTIDE-BASED DRUGS
11 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA
11.1 INTRODUCTION
11.2 RARE DISEASES
11.2.1 GROWING APPROVALS FOR ORPHAN DISEASES TO MAKE RARE DISEASES LARGEST THERAPEUTIC AREA FOR OLIGONUCLEOTIDE THERAPEUTICS
11.3 NEUROLOGICAL DISORDERS
11.3.1 COMMERCIAL SUCCESS OF RNA-TARGETED THERAPIES TO CONTINUE TO STRENGTHEN NEUROLOGY SEGMENT
11.4 CARDIOMETABOLIC DISEASES
11.4.1 EXPANDING RNA THERAPEUTICS FOR CARDIOVASCULAR DISEASES TO MAKE CARDIOMETABOLIC DISEASES FASTEST-GROWING THERAPEUTIC AREA
11.5 OTHER THERAPEUTIC AREAS
12 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER
12.1 INTRODUCTION
12.2 SPECIALTY CLINICS
12.2.1 GROWING NETWORK OF SPECIALIZED RARE DISEASE TREATMENT CENTERS TO MAINTAIN SPECIALTY CLINICS AS LARGEST END-USER SEGMENT
12.3 HOSPITALS
12.3.1 COMPLEX PATIENT MANAGEMENT AND ADMINISTRATION OF ADVANCED OLIGONUCLEOTIDE THERAPIES TO CONTINUE TO SUPPORT HOSPITAL DEMAND
12.4 HOME CARE SETTINGS
12.4.1 SHIFT TOWARD CONVENIENT DOSING AND SELF-ADMINISTRATION TO MAKE HOME CARE SETTINGS FASTEST-GROWING END-USER SEGMENT
12.5 OTHER END USERS
13 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE
13.1 INTRODUCTION
13.2 PRIMERS
13.2.1 WIDESPREAD USE OF PRIMERS ACROSS RESEARCH, DIAGNOSTICS, AND THERAPEUTIC DEVELOPMENT TO FUEL GROWTH
13.3 PROBES
13.3.1 EXPANDING MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE TO DRIVE STRONG DEMAND FOR PROBES
13.4 DNA OLIGONUCLEOTIDES
13.4.1 BROAD APPLICABILITY ACROSS LIFE SCIENCE RESEARCH AND DIAGNOSTICS TO DRIVE SIGNIFICANT MARKET SHARE FOR DNA OLIGOS
13.5 RNA OLIGONUCLEOTIDES
13.5.1 RAPID GROWTH OF RNA THERAPEUTICS AND GENE-EDITING TECHNOLOGIES TO DRIVE MARKET MOMENTUM FOR RNA OLIGOS
13.6 OTHER OLIGONUCLEOTIDES
14 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE
14.1 INTRODUCTION
14.2 CUSTOM OLIGONUCLEOTIDES
14.2.1 RAPID CLINICAL AND COMMERCIAL EXPANSION OF CHEMICALLY MODIFIED ANTISENSE AND SIRNA THERAPEUTICS TO MAKE CUSTOM OLIGONUCLEOTIDES FASTEST-GROWING SEGMENT
14.3 PREDESIGNED OLIGONUCLEOTIDES
14.3.1 PREDESIGNED OLIGONUCLEOTIDES CONTINUE TO WITNESS STEADY DEMAND OWING TO WIDESPREAD USE IN ROUTINE RESEARCH AND MOLECULAR DIAGNOSTICS
15 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION
15.1 INTRODUCTION
15.2 RESEARCH APPLICATIONS
15.2.1 PCR
15.2.1.1 Widespread adoption of PCR across life science research to drive market growth
15.2.2 NGS
15.2.2.1 Sequencing to continue to expand with increasing adoption of next-generation sequencing technologies
15.2.3 OTHER RESEARCH APPLICATIONS
15.3 THERAEPUTIC DEVELOPMENT
15.3.1 EXPANDING OLIGONUCLEOTIDE DRUG PIPELINES TO SUPPORT GROWTH OF MARKET FOR THERAPEUTIC DEVELOPMENT APPLICATIONS
15.4 DIAGNOSTIC APPLICATIONS
15.4.1 INCREASING ADOPTION OF MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE TO EXPAND MARKET FOR DIAGNOSTIC APPLICATIONS
16 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER
16.1 INTRODUCTION
16.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
16.2.1 EXPANDING OLIGONUCLEOTIDE DRUG PIPELINES TO MAKE PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES LARGEST END-USER SEGMENT
16.3 CROS & CDMOS
16.3.1 INCREASING OUTSOURCING OF OLIGONUCLEOTIDE DRUG DEVELOPMENT TO DRIVE FASTEST GROWTH AMONG CROS & CDMOS
16.4 DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES
16.4.1 GROWING ADOPTION OF MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE TO DRIVE DEMAND
16.5 ACADEMIC & RESEARCH INSTITUTES
16.5.1 EXPANDING GENOMICS AND LIFE SCIENCE RESEARCH TO SUSTAIN DEMAND FROM ACADEMIC & RESEARCH INSTITUTES
17 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE
17.1 INTRODUCTION
17.2 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES
17.2.1 OLIGONUCLEOTIDE SYNTHESIS REAGENTS
17.2.1.1 Phosphoramidite building blocks
17.2.1.1.1 DNA phosphoramidites
17.2.1.1.1.1 Steady, high-volume primer, probe, and gene-synthesis demand to anchor DNA phosphoramidites as largest phosphoramidite revenue category
17.2.1.1.2 RNA phosphoramidites
17.2.1.1.2.1 Expansion of siRNA and CRISPR guide RNA therapeutic pipeline to make RNA phosphoramidites fastest-growing phosphoramidite category
17.2.1.1.3 Modified phosphoramidites
17.2.1.1.3.1 Modified phosphoramidites to continue to gain importance as oligonucleotide complexity increases
17.2.1.2 Activators/Coupling reagents
17.2.1.2.1 Migration from standard tetrazole to ETT- and BTT-based activators to raise coupling efficiency in GMP-scale RNA and modified-oligo synthesis
17.2.1.3 Deprotection reagents
17.2.1.3.1 Rising synthesis throughput and demand for milder, modification-compatible deprotection chemistries to sustain detritylation reagent consumption
17.2.1.4 Capping reagents
17.2.1.4.1 Tightening n-1 impurity specifications for therapeutic oligonucleotides to lift demand for validated, high-purity capping reagent lots
17.2.1.5 Other reagents
17.2.2 SOLID SUPPORTS
17.2.2.1 Shift toward high-loading co-polymer CPG and single-use synthesis cassettes to support long-chain, GMP-scale oligonucleotide production
17.2.3 OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES
17.2.3.1 Tightening GMP purity specifications for therapeutic oligonucleotides to drive demand for purification and QC consumables
17.3 OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT
17.3.1 ADOPTION OF FLOW-THROUGH, GMP-COMPLIANT SYNTHESIS PLATFORMS TO SCALE OLIGONUCLEOTIDE MANUFACTURING FROM RESEARCH THROUGH COMMERCIAL PRODUCTION
18 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION
18.1 INTRODUCTION
18.2 RESEARCH APPLICATIONS
18.2.1 HIGH-VOLUME CONSUMPTION OF SYNTHESIS PRODUCTS ACROSS GENOMICS AND MOLECULAR BIOLOGY RESEARCH TO DRIVE GROWTH
18.3 THERAPEUTIC DEVELOPMENT
18.3.1 EXPANDING OLIGONUCLEOTIDE DRUG PIPELINES TO BOOST MARKET
18.4 DIAGNOSTIC APPLICATIONS
18.4.1 DIAGNOSTICS APPLICATIONS TO CONTINUE TO EXPAND WITH INCREASING ADOPTION OF MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE
19 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER
19.1 INTRODUCTION
19.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
19.2.1 INCREASING INVESTMENTS IN OLIGONUCLEOTIDE DRUG DEVELOPMENT AND MANUFACTURING TO SUPPORT MARKET GROWTH
19.3 CROS & CDMOS
19.3.1 INCREASING OUTSOURCING OF OLIGONUCLEOTIDE MANUFACTURING TO DRIVE MARKET GROWTH
19.4 DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES
19.4.1 EXPANDED USE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS WITH GROWTH OF MOLECULAR DIAGNOSTICS TO BOOST DEMAND
19.5 ACADEMIC & RESEARCH INSTITUTES
19.5.1 ACADEMICS & RESEARCH INSTITUTES TO CONTINUE TO PROVIDE STABLE DEMAND DRIVEN BY EXPANDING GENOMICS AND LIFE SCIENCE RESEARCH
20 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION
20.1 INTRODUCTION
20.2 NORTH AMERICA
20.2.1 US
20.2.1.1 Mature ecosystem across oligo-based therapeutics, synthesized oligonucleotides, and oligonucleotide synthesis products to drive market growth
20.2.2 CANADA
20.2.2.1 Strong academic research ecosystem to support market growth
20.3 EUROPE
20.3.1 GERMANY
20.3.1.1 Established capabilities for development and manufacturing of oligo-based therapeutics to drive market growth
20.3.2 UK
20.3.2.1 Established national programs to encourage utilization of oligonucleotide synthesis products
20.3.3 FRANCE
20.3.3.1 Increase in RNA-related research by biotechnology companies and academic institutions to drive market growth
20.3.4 ITALY
20.3.4.1 High demand for molecular diagnostics to favor adoption of oligonucleotide synthesis products
20.3.5 SPAIN
20.3.5.1 Government organizations investing in oligonucleotide-related research activities to drive market growth
20.3.6 REST OF EUROPE
20.4 ASIA PACIFIC
20.4.1 JAPAN
20.4.1.1 Expanding collaboration between pharma companies and academic institutions for development of oligonucleotide therapeutics to drive market growth
20.4.2 CHINA
20.4.2.1 Robust network of domestic companies offering oligonucleotide products to support market growth
20.4.3 INDIA
20.4.3.1 Expanding presence of domestic service providers to offer high-quality DNA and RNA oligonucleotides for research and diagnostics
20.4.4 SOUTH KOREA
20.4.4.1 High demand for custom oligonucleotide synthesis services to support market growth
20.4.5 AUSTRALIA
20.4.5.1 Well-established biomedical research sector to favor utilization of oligonucleotide synthesis products
20.4.6 REST OF ASIA PACIFIC
20.5 LATIN AMERICA
20.5.1 BRAZIL
20.5.1.1 Government initiatives aimed at strengthening genomic surveillance to offer market expansion opportunities
20.5.2 MEXICO
20.5.2.1 Growing network of pharmaceutical manufacturers and diagnostic laboratories to offer market expansion opportunities
20.5.3 ARGENTINA
20.5.3.1 Increasing investment by academic institutions in oligonucleotide-based research to offer market expansion opportunities
20.5.4 REST OF LATIN AMERICA
20.6 MIDDLE EAST
20.6.1 GCC COUNTRIES
20.6.1.1 Saudi Arabia
20.6.1.1.1 National genomics initiatives to encourage adoption of oligonucleotide synthesis products
20.6.1.2 UAE
20.6.1.2.1 Government-driven initiatives and substantial investments to improve UAE's capabilities in life science industry
20.6.1.3 Rest of GCC Countries
20.6.2 REST OF MIDDLE EAST
20.7 AFRICA
20.7.1 GROWING INVESTMENTS IN PUBLIC HEALTH DIAGNOSTICS AND GENOMIC SURVEILLANCE ACTIVITIES TO DRIVE MARKET GROWTH
21 COMPETITIVE LANDSCAPE
21.1 INTRODUCTION
21.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
21.2.1 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2023–2026
21.2.2 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2023–2026
21.3 REVENUE ANALYSIS, 2021–2025
21.3.1 REVENUE ANALYSIS FOR OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2021–2025
21.3.2 REVENUE ANALYSIS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2021–2025
21.4 MARKET SHARE ANALYSIS, 2025
21.4.1 MARKET SHARE ANALYSIS FOR OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2025
21.4.2 MARKET SHARE ANALYSIS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2025
21.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (OLIGONUCLEOTIDE-BASED DRUGS MARKET), 2025
21.5.1 STARS
21.5.2 EMERGING LEADERS
21.5.3 PERVASIVE PLAYERS
21.5.4 PARTICIPANTS
21.5.5 COMPANY FOOTPRINT: OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2025
21.5.5.1 Company footprint
21.5.5.2 Region footprint
21.5.5.3 Drug type footprint
21.5.5.4 Therapeutic area footprint
21.6 COMPANY EVALUATION MATRIX: KEY PLAYERS (OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET), 2025
21.6.1 STARS
21.6.2 EMERGING LEADERS
21.6.3 PERVASIVE PLAYERS
21.6.4 PARTICIPANTS
21.6.5 COMPANY FOOTPRINT: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2025
21.6.5.1 Company footprint
21.6.5.2 Region footprint
21.6.5.3 Product type footprint
21.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
21.7.1 PROGRESSIVE COMPANIES
21.7.2 RESPONSIVE COMPANIES
21.7.3 DYNAMIC COMPANIES
21.7.4 STARTING BLOCKS
21.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
21.7.5.1 Detailed list of key startups/SMEs
21.7.5.2 Competitive benchmarking of key startups/SMEs
21.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
21.9 COMPANY VALUATION & FINANCIAL METRICS
21.9.1 COMPANY VALUATION & FINANCIAL METRICS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES PLAYERS
21.9.2 COMPANY VALUATION & FINANCIAL METRICS FOR OLIGONUCLEOTIDE-BASE DRUGS PLAYERS
21.10 COMPETITIVE SCENARIO
21.10.1 PRODUCT APPROVALS
21.10.2 DEALS
21.10.3 EXPANSIONS
22 COMPANY PROFILES
22.1 OLIGONUCLEOTIDE-BASED DRUG COMPANIES
22.1.1 ALNYLAM PHARMACEUTICALS, INC.
22.1.1.1 Business overview
22.1.1.2 Products offered
22.1.1.3 Recent developments
22.1.1.3.1 Product approvals
22.1.1.3.2 Deals
22.1.1.3.3 Expansions
22.1.1.4 MnM view
22.1.1.4.1 Key strengths
22.1.1.4.2 Strategic choices
22.1.1.4.3 Weaknesses & competitive threats
22.1.2 BIOGEN INC.
22.1.2.1 Business overview
22.1.2.2 Products offered
22.1.2.3 Recent developments
22.1.2.3.1 Product approvals
22.1.2.3.2 Deals
22.1.2.3.3 Expansions
22.1.2.4 MnM view
22.1.2.4.1 Key strengths
22.1.2.4.2 Strategic choices
22.1.2.4.3 Weaknesses & competitive threats
22.1.3 NOVARTIS AG
22.1.3.1 Business overview
22.1.3.2 Products offered
22.1.3.3 Recent developments
22.1.3.3.1 Product approvals
22.1.3.3.2 Deals
22.1.3.4 MnM view
22.1.3.4.1 Key strengths
22.1.3.4.2 Strategic choices
22.1.3.4.3 Weaknesses & competitive threats
22.1.4 SAREPTA THERAPEUTICS, INC.
22.1.4.1 Business overview
22.1.4.2 Products offered
22.1.4.3 Recent developments
22.1.4.3.1 Product approvals
22.1.4.3.2 Deals
22.1.4.3.3 Expansions
22.1.4.4 MnM view
22.1.4.4.1 Key strengths
22.1.4.4.2 Strategic choices
22.1.4.4.3 Weaknesses & competitive threats
22.1.5 ASTELLAS PHARMA INC.
22.1.5.1 Business overview
22.1.5.2 Products offered
22.1.5.3 Recent developments
22.1.5.3.1 Product approvals
22.1.5.3.2 Deals
22.1.5.4 MnM view
22.1.5.4.1 Key strengths
22.1.5.4.2 Strategic choices
22.1.5.4.3 Weaknesses & competitive threats
22.1.6 ASTRAZENECA
22.1.6.1 Business overview
22.1.6.2 Products offered
22.1.6.3 Recent developments
22.1.6.3.1 Product approvals
22.1.6.3.2 Deals
22.1.7 JAZZ PHARMACEUTICALS PLC
22.1.7.1 Business overview
22.1.7.2 Products offered
22.1.8 GERON CORPORATION
22.1.8.1 Business overview
22.1.8.2 Products offered
22.1.8.3 Recent developments
22.1.8.3.1 Product approvals
22.1.8.3.2 Deals
22.1.9 IONIS PHARMACEUTICALS, INC.
22.1.9.1 Business overview
22.1.9.2 Products offered
22.1.9.3 Recent developments
22.1.9.3.1 Product approvals
22.1.9.3.2 Deals
22.1.9.3.3 Expansions
22.1.10 NIPPON SHINYAKU, CO. LTD. (NS PHARMA, INC.)
22.1.10.1 Business overview
22.1.10.2 Products offered
22.1.10.3 Recent developments
22.1.10.3.1 Deals
22.1.11 NOVO NORDISK A/S
22.1.11.1 Business overview
22.1.11.2 Products offered
22.1.11.3 Recent developments
22.1.11.3.1 Product approvals
22.1.12 ARROWHEAD PHARMACEUTICALS, INC.
22.1.12.1 Business overview
22.1.12.2 Products offered
22.1.12.3 Recent developments
22.1.12.3.1 Product launches & approvals
22.1.12.3.2 Deals
22.1.13 SANOFI
22.1.13.1 Business overview
22.1.13.2 Products offered
22.1.13.3 Recent developments
22.1.13.3.1 Product approvals
22.2 OLIGONUCLEOTIDE SYNTHESIS & SYNTHESIZED OLIGONUCLEOTIDE COMPANIES
22.2.1 THERMO FISHER SCIENTIFIC INC.
22.2.1.1 Business overview
22.2.1.2 Products offered
22.2.1.3 Recent developments
22.2.1.3.1 Expansions
22.2.1.4 MnM view
22.2.1.4.1 Key strengths
22.2.1.4.2 Strategic choices
22.2.1.4.3 Weaknesses & competitive threats
22.2.2 MERCK KGAA
22.2.2.1 Business overview
22.2.2.2 Products offered
22.2.2.3 Recent developments
22.2.2.3.1 Expansions
22.2.2.4 MnM view
22.2.2.4.1 Key strengths
22.2.2.4.2 Strategic choices
22.2.2.4.3 Weaknesses & competitive threats
22.2.3 DANAHER CORPORATION
22.2.3.1 Business overview
22.2.3.2 Products offered
22.2.3.3 Recent developments
22.2.3.3.1 Service launches
22.2.3.3.2 Deals
22.2.3.3.3 Expansions
22.2.3.4 MnM view
22.2.3.4.1 Key strengths
22.2.3.4.2 Strategic choices
22.2.3.4.3 Weaknesses & competitive threats
22.2.4 EUROFINS SCIENTIFIC
22.2.4.1 Business overview
22.2.4.2 Products offered
22.2.4.3 Recent developments
22.2.4.3.1 Deals
22.2.4.3.2 Expansions
22.2.4.4 MnM view
22.2.4.4.1 Key strengths
22.2.4.4.2 Strategic choices
22.2.4.4.3 Weaknesses & competitive threats
22.2.5 AGILENT TECHNOLOGIES, INC.
22.2.5.1 Business overview
22.2.5.2 Products offered
22.2.5.3 Recent developments
22.2.5.3.1 Deals
22.2.5.3.2 Expansions
22.2.6 LGC LIMITED
22.2.6.1 Business overview
22.2.6.2 Products offered
22.2.6.3 Recent developments
22.2.6.3.1 Deals
22.2.6.4 MnM view
22.2.6.4.1 Key strengths
22.2.6.4.2 Strategic choices
22.2.6.4.3 Weaknesses & competitive threats
22.2.7 TWIST BIOSCIENCE
22.2.7.1 Business overview
22.2.7.2 Products offered
22.2.7.3 Recent developments
22.2.7.3.1 Product/Service launches
22.2.7.3.2 Deals
22.2.8 GENSCRIPT
22.2.8.1 Business overview
22.2.8.2 Products offered
22.2.8.3 Recent developments
22.2.8.3.1 Product/Service launches
22.2.8.3.2 Deals
22.2.8.3.3 Expansions
22.2.9 MARAVAI LIFESCIENCES
22.2.9.1 Business overview
22.2.9.2 Products offered
22.2.9.3 Recent developments
22.2.9.3.1 Product/Service launches
22.2.9.3.2 Deals
22.2.9.3.3 Expansions
22.2.9.4 MnM view
22.2.9.4.1 Key strengths
22.2.9.4.2 Strategic choices
22.2.9.4.3 Weaknesses & competitive threats
22.2.10 KANEKA CORPORATION
22.2.10.1 Business overview
22.2.10.2 Products offered
22.2.10.3 Recent developments
22.2.10.3.1 Expansions
22.2.11 AZENTA US INC.
22.2.11.1 Business overview
22.2.11.2 Products offered
22.2.11.3 Recent developments
22.2.11.3.1 Product/Service launches
22.2.11.3.2 Deals
22.2.12 OLIGOMAKER APS (PART OF TAG COPENHAGEN A/S)
22.2.12.1 Business overview
22.2.12.2 Products offered
22.2.13 BIOLEGIO B.V.
22.2.13.1 Business overview
22.2.13.2 Products offered
22.2.14 BIOLYTIC LAB PERFORMANCE, INC.
22.2.14.1 Business overview
22.2.14.2 Products offered
22.2.14.3 Recent developments
22.2.14.3.1 Product/Service launches
22.2.15 REVVITY (THROUGH SUBSIDIARY HORIZON DISCOVERY LTD.)
22.2.15.1 Business overview
22.2.15.2 Products offered
22.2.15.3 Recent developments
22.2.15.3.1 Product/Service launches
22.2.16 BIO-SYNTHESIS, INC.
22.2.16.1 Business overview
22.2.16.2 Products offered
22.2.17 CREATIVE BIOGENE
22.2.17.1 Business overview
22.2.17.2 Products offered
22.2.18 REPROCELL INC. (THROUGH SUBSIDIARY BIOSERVE)
22.2.18.1 Business overview
22.2.18.2 Products offered
22.2.19 BIOCOMMA LIMITED
22.2.19.1 Business overview
22.2.19.2 Products offered
23 RESEARCH METHODOLOGY
23.1 RESEARCH DATA
23.1.1 SECONDARY DATA
23.1.1.1 Key secondary sources
23.1.1.2 Key data from secondary research
23.1.2 PRIMARY DATA
23.1.2.1 Key primary participants
23.1.2.2 Breakdown of primary interviews
23.1.2.3 Key data from primary sources
23.2 MARKET SIZE ESTIMATION
23.2.1 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET ESTIMATION, 2025
23.2.1.1 Approach 1: Company revenue analysis-based estimation (bottom-up)
23.2.1.2 Approach 2: Secondary research
23.2.1.3 Approach 3: Primary research
23.2.1.4 Key industry insights
23.2.1.5 Approach 3: MnM repository analysis
23.2.2 SEGMENTAL MARKET SIZE ESTIMATION, 2025
23.3 MARKET GROWTH RATE PROJECTIONS
23.4 DATA TRIANGULATION
23.5 RESEARCH ASSUMPTIONS
23.6 RESEARCH LIMITATIONS & RISK ASSESSMENT
24 APPENDIX
24.1 DISCUSSION GUIDE
24.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
24.3 CUSTOMIZATION OPTIONS
24.4 RELATED REPORTS
24.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONS COVERED
1.3.2 REGIONS COVERED
1.3.3 INCLUSIONS & EXCLUSIONS
1.3.4 YEARS CONSIDERED
1.3.5 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN OLIGONUCLEOTIDE SYNTHESIS MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
3.2 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING AND COUNTRY, 2025
3.3 OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
3.4 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY OFFERING, 2026 VS. 2031 (%)
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Rising commercialization and regulatory approvals of oligonucleotide therapeutics
4.2.1.2 Expanding RNA therapeutics pipeline and adoption of chemically modified oligos
4.2.1.3 Growing use of PCR, qPCR, NGS, CRISPR, synthetic biology, and molecular diagnostics
4.2.1.4 Increasing outsourcing of oligonucleotide synthesis and GMP manufacturing to CROs/CDMOs
4.2.2 RESTRAINTS
4.2.2.1 Complexity of large-scale oligonucleotide manufacturing and analytical control
4.2.3 OPPORTUNITIES
4.2.3.1 Increasing government and industry investments in life sciences, RNA therapeutics, and manufacturing infrastructure
4.2.3.2 Expansion of oligonucleotide therapeutics into cardiometabolic and common chronic diseases
4.2.3.3 Growth of companion diagnostics and precision medicine
4.2.4 CHALLENGES
4.2.4.1 Lack of standard regulations
4.2.4.2 Delivery of oligonucleotide drugs to specific targets
4.2.4.3 Sustainability & waste management in phosphoramidite-based synthesis
4.3 UNMET NEEDS & WHITE SPACES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
4.5.1 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS IN THE OLIGONUCLEOTIDE-BASED DRUGS MARKET
4.5.2 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS IN OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 OLIGONUCLEOTIDE-BASED DRUGS
5.1.1.1 Threat of new entrants
5.1.1.2 Threat of substitutes
5.1.1.3 Bargaining power of buyers
5.1.1.4 Bargaining power of suppliers
5.1.1.5 Intensity of competitive rivalry
5.1.2 SYNTHESIZED OLIGONUCLEOTIDES & OLIGONUCLEOTIDE SYNTHESIS PRODUCTS
5.1.2.1 Threat of new entrants
5.1.2.2 Threat of substitutes
5.1.2.3 Bargaining power of buyers
5.1.2.4 Bargaining power of suppliers
5.1.2.5 Intensity of competitive rivalry
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS & FORECAST
5.2.3 TRENDS IN GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY KEY PLAYER, 2022–2025
5.5.2 AVERAGE SELLING PRICE OF EQUIPMENT, BY REGION, 2025
5.6 KEY CONFERENCES & EVENTS, 2026–2027
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.8 INVESTMENT & FUNDING ACTIVITY
5.9 IMPACT OF 2025 US TARIFFS ON OLIGONUCLEOTIDE SYNTHESIS MARKET
5.9.1 INTRODUCTION
5.9.2 KEY TARIFF RATES
5.9.3 PRICE IMPACT ANALYSIS
5.9.4 IMPACT ON COUNTRY/REGION
5.9.4.1 North America
5.9.4.2 Europe
5.9.4.3 Asia Pacific
5.9.5 IMPACT ON END-USE INDUSTRIES
5.9.5.1 Hospitals
5.9.5.2 Specialty clinics
5.9.5.3 Home care settings & other end users
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 TECHNOLOGY ANALYSIS
6.1.1 KEY TECHNOLOGIES
6.1.1.1 Solid-phase phosphoramidite synthesis and scale-up
6.1.1.2 Liquid-phase synthesis
6.1.1.3 Chemical modification & backbone engineering
6.1.1.4 Conjugation & targeted delivery chemistry
6.1.1.5 Enzymatic & novel synthesis technologies
6.1.1.6 High-throughput automated oligonucleotide synthesis
6.1.1.7 Purification & analytical characterization
6.1.2 ADJACENT TECHNOLOGIES
6.1.2.1 Molecular biology & genomic technologies
6.1.2.2 Synthetic biology & gene synthesis
6.1.3 COMPLEMENTARY TECHNOLOGIES
6.1.3.1 Advanced oligonucleotide delivery technologies
6.1.3.2 AI-assisted oligonucleotide design
6.2 TECHNOLOGY/PRODUCT ROADMAP
6.3 FUTURE APPLICATIONS
6.4 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE SYNTHESIS MARKET
6.4.1 TOP USE CASES & MARKET POTENTIAL
6.4.2 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
6.4.3 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN OLIGONUCLEOTIDE SYNTHESIS MARKET
6.5 PATENT ANALYSIS & INNOVATIONS
6.5.1 OLIGONUCLEOTIDE SYNTHESIS MARKET: PATENT ANALYSIS, 2015–2025
6.5.2 KEY INNOVATIONS
7 SUSTAINABILITY & REGULATORY LANDSCAPE
7.1 REGIONAL REGULATIONS & COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 REGULATORY FRAMEWORK & REIMBURSEMENT
7.1.2.1 North America
7.1.2.2 Europe
7.1.2.3 Asia Pacific
7.1.2.4 Rest of the World
7.1.3 INDUSTRY STANDARDS
7.2 REIMBURSEMENT SCENARIO
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 KEY BUYING CRITERIA, BY END USER
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM END USERS
8.5 MARKET PROFITABILITY
9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING
9.1 INTRODUCTION
9.2 OLIGONUCLEOTIDE-BASED DRUGS
9.2.1 RECURRING CONSUMABLES DEMAND, AUTOMATION UPGRADES, AND ADVANCED SCREENING PLATFORMS TO DRIVE GROWTH
9.3 SYNTHESIZED OLIGONUCLEOTIDES
9.3.1 GROWING ADOPTION OF PCR, QPCR, NGS, AND CRISPR-BASED GENOME EDITING TO GENERATE SUBSTANTIAL DEMAND FOR CUSTOM PRIMERS
9.4 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS
9.4.1 INCREASING INSTALLATION OF AUTOMATED OLIGONUCLEOTIDE SYNTHESIZERS TO SUPPORT MARKET GROWTH
10 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE
10.1 INTRODUCTION
10.2 ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS
10.2.1 ASO-BASED DRUGS ACCOUNTED FOR LARGEST MARKET SHARE DUE TO THEIR ESTABLISHED CLINICAL SUCCESS ACROSS RARE AND NEUROLOGICAL DISEASES
10.3 SIRNA OLIGONUCLEOTIDE-BASED DRUGS
10.3.1 EXPANDING COMMERCIAL ADOPTION AND STRONG LATE-STAGE PIPELINES TO DRIVE GROWTH
10.4 OTHER OLIGONUCLEOTIDE-BASED DRUGS
11 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA
11.1 INTRODUCTION
11.2 RARE DISEASES
11.2.1 GROWING APPROVALS FOR ORPHAN DISEASES TO MAKE RARE DISEASES LARGEST THERAPEUTIC AREA FOR OLIGONUCLEOTIDE THERAPEUTICS
11.3 NEUROLOGICAL DISORDERS
11.3.1 COMMERCIAL SUCCESS OF RNA-TARGETED THERAPIES TO CONTINUE TO STRENGTHEN NEUROLOGY SEGMENT
11.4 CARDIOMETABOLIC DISEASES
11.4.1 EXPANDING RNA THERAPEUTICS FOR CARDIOVASCULAR DISEASES TO MAKE CARDIOMETABOLIC DISEASES FASTEST-GROWING THERAPEUTIC AREA
11.5 OTHER THERAPEUTIC AREAS
12 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER
12.1 INTRODUCTION
12.2 SPECIALTY CLINICS
12.2.1 GROWING NETWORK OF SPECIALIZED RARE DISEASE TREATMENT CENTERS TO MAINTAIN SPECIALTY CLINICS AS LARGEST END-USER SEGMENT
12.3 HOSPITALS
12.3.1 COMPLEX PATIENT MANAGEMENT AND ADMINISTRATION OF ADVANCED OLIGONUCLEOTIDE THERAPIES TO CONTINUE TO SUPPORT HOSPITAL DEMAND
12.4 HOME CARE SETTINGS
12.4.1 SHIFT TOWARD CONVENIENT DOSING AND SELF-ADMINISTRATION TO MAKE HOME CARE SETTINGS FASTEST-GROWING END-USER SEGMENT
12.5 OTHER END USERS
13 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE
13.1 INTRODUCTION
13.2 PRIMERS
13.2.1 WIDESPREAD USE OF PRIMERS ACROSS RESEARCH, DIAGNOSTICS, AND THERAPEUTIC DEVELOPMENT TO FUEL GROWTH
13.3 PROBES
13.3.1 EXPANDING MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE TO DRIVE STRONG DEMAND FOR PROBES
13.4 DNA OLIGONUCLEOTIDES
13.4.1 BROAD APPLICABILITY ACROSS LIFE SCIENCE RESEARCH AND DIAGNOSTICS TO DRIVE SIGNIFICANT MARKET SHARE FOR DNA OLIGOS
13.5 RNA OLIGONUCLEOTIDES
13.5.1 RAPID GROWTH OF RNA THERAPEUTICS AND GENE-EDITING TECHNOLOGIES TO DRIVE MARKET MOMENTUM FOR RNA OLIGOS
13.6 OTHER OLIGONUCLEOTIDES
14 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE
14.1 INTRODUCTION
14.2 CUSTOM OLIGONUCLEOTIDES
14.2.1 RAPID CLINICAL AND COMMERCIAL EXPANSION OF CHEMICALLY MODIFIED ANTISENSE AND SIRNA THERAPEUTICS TO MAKE CUSTOM OLIGONUCLEOTIDES FASTEST-GROWING SEGMENT
14.3 PREDESIGNED OLIGONUCLEOTIDES
14.3.1 PREDESIGNED OLIGONUCLEOTIDES CONTINUE TO WITNESS STEADY DEMAND OWING TO WIDESPREAD USE IN ROUTINE RESEARCH AND MOLECULAR DIAGNOSTICS
15 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION
15.1 INTRODUCTION
15.2 RESEARCH APPLICATIONS
15.2.1 PCR
15.2.1.1 Widespread adoption of PCR across life science research to drive market growth
15.2.2 NGS
15.2.2.1 Sequencing to continue to expand with increasing adoption of next-generation sequencing technologies
15.2.3 OTHER RESEARCH APPLICATIONS
15.3 THERAEPUTIC DEVELOPMENT
15.3.1 EXPANDING OLIGONUCLEOTIDE DRUG PIPELINES TO SUPPORT GROWTH OF MARKET FOR THERAPEUTIC DEVELOPMENT APPLICATIONS
15.4 DIAGNOSTIC APPLICATIONS
15.4.1 INCREASING ADOPTION OF MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE TO EXPAND MARKET FOR DIAGNOSTIC APPLICATIONS
16 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER
16.1 INTRODUCTION
16.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
16.2.1 EXPANDING OLIGONUCLEOTIDE DRUG PIPELINES TO MAKE PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES LARGEST END-USER SEGMENT
16.3 CROS & CDMOS
16.3.1 INCREASING OUTSOURCING OF OLIGONUCLEOTIDE DRUG DEVELOPMENT TO DRIVE FASTEST GROWTH AMONG CROS & CDMOS
16.4 DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES
16.4.1 GROWING ADOPTION OF MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE TO DRIVE DEMAND
16.5 ACADEMIC & RESEARCH INSTITUTES
16.5.1 EXPANDING GENOMICS AND LIFE SCIENCE RESEARCH TO SUSTAIN DEMAND FROM ACADEMIC & RESEARCH INSTITUTES
17 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE
17.1 INTRODUCTION
17.2 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES
17.2.1 OLIGONUCLEOTIDE SYNTHESIS REAGENTS
17.2.1.1 Phosphoramidite building blocks
17.2.1.1.1 DNA phosphoramidites
17.2.1.1.1.1 Steady, high-volume primer, probe, and gene-synthesis demand to anchor DNA phosphoramidites as largest phosphoramidite revenue category
17.2.1.1.2 RNA phosphoramidites
17.2.1.1.2.1 Expansion of siRNA and CRISPR guide RNA therapeutic pipeline to make RNA phosphoramidites fastest-growing phosphoramidite category
17.2.1.1.3 Modified phosphoramidites
17.2.1.1.3.1 Modified phosphoramidites to continue to gain importance as oligonucleotide complexity increases
17.2.1.2 Activators/Coupling reagents
17.2.1.2.1 Migration from standard tetrazole to ETT- and BTT-based activators to raise coupling efficiency in GMP-scale RNA and modified-oligo synthesis
17.2.1.3 Deprotection reagents
17.2.1.3.1 Rising synthesis throughput and demand for milder, modification-compatible deprotection chemistries to sustain detritylation reagent consumption
17.2.1.4 Capping reagents
17.2.1.4.1 Tightening n-1 impurity specifications for therapeutic oligonucleotides to lift demand for validated, high-purity capping reagent lots
17.2.1.5 Other reagents
17.2.2 SOLID SUPPORTS
17.2.2.1 Shift toward high-loading co-polymer CPG and single-use synthesis cassettes to support long-chain, GMP-scale oligonucleotide production
17.2.3 OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES
17.2.3.1 Tightening GMP purity specifications for therapeutic oligonucleotides to drive demand for purification and QC consumables
17.3 OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT
17.3.1 ADOPTION OF FLOW-THROUGH, GMP-COMPLIANT SYNTHESIS PLATFORMS TO SCALE OLIGONUCLEOTIDE MANUFACTURING FROM RESEARCH THROUGH COMMERCIAL PRODUCTION
18 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION
18.1 INTRODUCTION
18.2 RESEARCH APPLICATIONS
18.2.1 HIGH-VOLUME CONSUMPTION OF SYNTHESIS PRODUCTS ACROSS GENOMICS AND MOLECULAR BIOLOGY RESEARCH TO DRIVE GROWTH
18.3 THERAPEUTIC DEVELOPMENT
18.3.1 EXPANDING OLIGONUCLEOTIDE DRUG PIPELINES TO BOOST MARKET
18.4 DIAGNOSTIC APPLICATIONS
18.4.1 DIAGNOSTICS APPLICATIONS TO CONTINUE TO EXPAND WITH INCREASING ADOPTION OF MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE
19 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER
19.1 INTRODUCTION
19.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
19.2.1 INCREASING INVESTMENTS IN OLIGONUCLEOTIDE DRUG DEVELOPMENT AND MANUFACTURING TO SUPPORT MARKET GROWTH
19.3 CROS & CDMOS
19.3.1 INCREASING OUTSOURCING OF OLIGONUCLEOTIDE MANUFACTURING TO DRIVE MARKET GROWTH
19.4 DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES
19.4.1 EXPANDED USE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS WITH GROWTH OF MOLECULAR DIAGNOSTICS TO BOOST DEMAND
19.5 ACADEMIC & RESEARCH INSTITUTES
19.5.1 ACADEMICS & RESEARCH INSTITUTES TO CONTINUE TO PROVIDE STABLE DEMAND DRIVEN BY EXPANDING GENOMICS AND LIFE SCIENCE RESEARCH
20 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION
20.1 INTRODUCTION
20.2 NORTH AMERICA
20.2.1 US
20.2.1.1 Mature ecosystem across oligo-based therapeutics, synthesized oligonucleotides, and oligonucleotide synthesis products to drive market growth
20.2.2 CANADA
20.2.2.1 Strong academic research ecosystem to support market growth
20.3 EUROPE
20.3.1 GERMANY
20.3.1.1 Established capabilities for development and manufacturing of oligo-based therapeutics to drive market growth
20.3.2 UK
20.3.2.1 Established national programs to encourage utilization of oligonucleotide synthesis products
20.3.3 FRANCE
20.3.3.1 Increase in RNA-related research by biotechnology companies and academic institutions to drive market growth
20.3.4 ITALY
20.3.4.1 High demand for molecular diagnostics to favor adoption of oligonucleotide synthesis products
20.3.5 SPAIN
20.3.5.1 Government organizations investing in oligonucleotide-related research activities to drive market growth
20.3.6 REST OF EUROPE
20.4 ASIA PACIFIC
20.4.1 JAPAN
20.4.1.1 Expanding collaboration between pharma companies and academic institutions for development of oligonucleotide therapeutics to drive market growth
20.4.2 CHINA
20.4.2.1 Robust network of domestic companies offering oligonucleotide products to support market growth
20.4.3 INDIA
20.4.3.1 Expanding presence of domestic service providers to offer high-quality DNA and RNA oligonucleotides for research and diagnostics
20.4.4 SOUTH KOREA
20.4.4.1 High demand for custom oligonucleotide synthesis services to support market growth
20.4.5 AUSTRALIA
20.4.5.1 Well-established biomedical research sector to favor utilization of oligonucleotide synthesis products
20.4.6 REST OF ASIA PACIFIC
20.5 LATIN AMERICA
20.5.1 BRAZIL
20.5.1.1 Government initiatives aimed at strengthening genomic surveillance to offer market expansion opportunities
20.5.2 MEXICO
20.5.2.1 Growing network of pharmaceutical manufacturers and diagnostic laboratories to offer market expansion opportunities
20.5.3 ARGENTINA
20.5.3.1 Increasing investment by academic institutions in oligonucleotide-based research to offer market expansion opportunities
20.5.4 REST OF LATIN AMERICA
20.6 MIDDLE EAST
20.6.1 GCC COUNTRIES
20.6.1.1 Saudi Arabia
20.6.1.1.1 National genomics initiatives to encourage adoption of oligonucleotide synthesis products
20.6.1.2 UAE
20.6.1.2.1 Government-driven initiatives and substantial investments to improve UAE's capabilities in life science industry
20.6.1.3 Rest of GCC Countries
20.6.2 REST OF MIDDLE EAST
20.7 AFRICA
20.7.1 GROWING INVESTMENTS IN PUBLIC HEALTH DIAGNOSTICS AND GENOMIC SURVEILLANCE ACTIVITIES TO DRIVE MARKET GROWTH
21 COMPETITIVE LANDSCAPE
21.1 INTRODUCTION
21.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
21.2.1 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2023–2026
21.2.2 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2023–2026
21.3 REVENUE ANALYSIS, 2021–2025
21.3.1 REVENUE ANALYSIS FOR OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2021–2025
21.3.2 REVENUE ANALYSIS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2021–2025
21.4 MARKET SHARE ANALYSIS, 2025
21.4.1 MARKET SHARE ANALYSIS FOR OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2025
21.4.2 MARKET SHARE ANALYSIS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2025
21.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (OLIGONUCLEOTIDE-BASED DRUGS MARKET), 2025
21.5.1 STARS
21.5.2 EMERGING LEADERS
21.5.3 PERVASIVE PLAYERS
21.5.4 PARTICIPANTS
21.5.5 COMPANY FOOTPRINT: OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2025
21.5.5.1 Company footprint
21.5.5.2 Region footprint
21.5.5.3 Drug type footprint
21.5.5.4 Therapeutic area footprint
21.6 COMPANY EVALUATION MATRIX: KEY PLAYERS (OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET), 2025
21.6.1 STARS
21.6.2 EMERGING LEADERS
21.6.3 PERVASIVE PLAYERS
21.6.4 PARTICIPANTS
21.6.5 COMPANY FOOTPRINT: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2025
21.6.5.1 Company footprint
21.6.5.2 Region footprint
21.6.5.3 Product type footprint
21.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
21.7.1 PROGRESSIVE COMPANIES
21.7.2 RESPONSIVE COMPANIES
21.7.3 DYNAMIC COMPANIES
21.7.4 STARTING BLOCKS
21.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
21.7.5.1 Detailed list of key startups/SMEs
21.7.5.2 Competitive benchmarking of key startups/SMEs
21.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
21.9 COMPANY VALUATION & FINANCIAL METRICS
21.9.1 COMPANY VALUATION & FINANCIAL METRICS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES PLAYERS
21.9.2 COMPANY VALUATION & FINANCIAL METRICS FOR OLIGONUCLEOTIDE-BASE DRUGS PLAYERS
21.10 COMPETITIVE SCENARIO
21.10.1 PRODUCT APPROVALS
21.10.2 DEALS
21.10.3 EXPANSIONS
22 COMPANY PROFILES
22.1 OLIGONUCLEOTIDE-BASED DRUG COMPANIES
22.1.1 ALNYLAM PHARMACEUTICALS, INC.
22.1.1.1 Business overview
22.1.1.2 Products offered
22.1.1.3 Recent developments
22.1.1.3.1 Product approvals
22.1.1.3.2 Deals
22.1.1.3.3 Expansions
22.1.1.4 MnM view
22.1.1.4.1 Key strengths
22.1.1.4.2 Strategic choices
22.1.1.4.3 Weaknesses & competitive threats
22.1.2 BIOGEN INC.
22.1.2.1 Business overview
22.1.2.2 Products offered
22.1.2.3 Recent developments
22.1.2.3.1 Product approvals
22.1.2.3.2 Deals
22.1.2.3.3 Expansions
22.1.2.4 MnM view
22.1.2.4.1 Key strengths
22.1.2.4.2 Strategic choices
22.1.2.4.3 Weaknesses & competitive threats
22.1.3 NOVARTIS AG
22.1.3.1 Business overview
22.1.3.2 Products offered
22.1.3.3 Recent developments
22.1.3.3.1 Product approvals
22.1.3.3.2 Deals
22.1.3.4 MnM view
22.1.3.4.1 Key strengths
22.1.3.4.2 Strategic choices
22.1.3.4.3 Weaknesses & competitive threats
22.1.4 SAREPTA THERAPEUTICS, INC.
22.1.4.1 Business overview
22.1.4.2 Products offered
22.1.4.3 Recent developments
22.1.4.3.1 Product approvals
22.1.4.3.2 Deals
22.1.4.3.3 Expansions
22.1.4.4 MnM view
22.1.4.4.1 Key strengths
22.1.4.4.2 Strategic choices
22.1.4.4.3 Weaknesses & competitive threats
22.1.5 ASTELLAS PHARMA INC.
22.1.5.1 Business overview
22.1.5.2 Products offered
22.1.5.3 Recent developments
22.1.5.3.1 Product approvals
22.1.5.3.2 Deals
22.1.5.4 MnM view
22.1.5.4.1 Key strengths
22.1.5.4.2 Strategic choices
22.1.5.4.3 Weaknesses & competitive threats
22.1.6 ASTRAZENECA
22.1.6.1 Business overview
22.1.6.2 Products offered
22.1.6.3 Recent developments
22.1.6.3.1 Product approvals
22.1.6.3.2 Deals
22.1.7 JAZZ PHARMACEUTICALS PLC
22.1.7.1 Business overview
22.1.7.2 Products offered
22.1.8 GERON CORPORATION
22.1.8.1 Business overview
22.1.8.2 Products offered
22.1.8.3 Recent developments
22.1.8.3.1 Product approvals
22.1.8.3.2 Deals
22.1.9 IONIS PHARMACEUTICALS, INC.
22.1.9.1 Business overview
22.1.9.2 Products offered
22.1.9.3 Recent developments
22.1.9.3.1 Product approvals
22.1.9.3.2 Deals
22.1.9.3.3 Expansions
22.1.10 NIPPON SHINYAKU, CO. LTD. (NS PHARMA, INC.)
22.1.10.1 Business overview
22.1.10.2 Products offered
22.1.10.3 Recent developments
22.1.10.3.1 Deals
22.1.11 NOVO NORDISK A/S
22.1.11.1 Business overview
22.1.11.2 Products offered
22.1.11.3 Recent developments
22.1.11.3.1 Product approvals
22.1.12 ARROWHEAD PHARMACEUTICALS, INC.
22.1.12.1 Business overview
22.1.12.2 Products offered
22.1.12.3 Recent developments
22.1.12.3.1 Product launches & approvals
22.1.12.3.2 Deals
22.1.13 SANOFI
22.1.13.1 Business overview
22.1.13.2 Products offered
22.1.13.3 Recent developments
22.1.13.3.1 Product approvals
22.2 OLIGONUCLEOTIDE SYNTHESIS & SYNTHESIZED OLIGONUCLEOTIDE COMPANIES
22.2.1 THERMO FISHER SCIENTIFIC INC.
22.2.1.1 Business overview
22.2.1.2 Products offered
22.2.1.3 Recent developments
22.2.1.3.1 Expansions
22.2.1.4 MnM view
22.2.1.4.1 Key strengths
22.2.1.4.2 Strategic choices
22.2.1.4.3 Weaknesses & competitive threats
22.2.2 MERCK KGAA
22.2.2.1 Business overview
22.2.2.2 Products offered
22.2.2.3 Recent developments
22.2.2.3.1 Expansions
22.2.2.4 MnM view
22.2.2.4.1 Key strengths
22.2.2.4.2 Strategic choices
22.2.2.4.3 Weaknesses & competitive threats
22.2.3 DANAHER CORPORATION
22.2.3.1 Business overview
22.2.3.2 Products offered
22.2.3.3 Recent developments
22.2.3.3.1 Service launches
22.2.3.3.2 Deals
22.2.3.3.3 Expansions
22.2.3.4 MnM view
22.2.3.4.1 Key strengths
22.2.3.4.2 Strategic choices
22.2.3.4.3 Weaknesses & competitive threats
22.2.4 EUROFINS SCIENTIFIC
22.2.4.1 Business overview
22.2.4.2 Products offered
22.2.4.3 Recent developments
22.2.4.3.1 Deals
22.2.4.3.2 Expansions
22.2.4.4 MnM view
22.2.4.4.1 Key strengths
22.2.4.4.2 Strategic choices
22.2.4.4.3 Weaknesses & competitive threats
22.2.5 AGILENT TECHNOLOGIES, INC.
22.2.5.1 Business overview
22.2.5.2 Products offered
22.2.5.3 Recent developments
22.2.5.3.1 Deals
22.2.5.3.2 Expansions
22.2.6 LGC LIMITED
22.2.6.1 Business overview
22.2.6.2 Products offered
22.2.6.3 Recent developments
22.2.6.3.1 Deals
22.2.6.4 MnM view
22.2.6.4.1 Key strengths
22.2.6.4.2 Strategic choices
22.2.6.4.3 Weaknesses & competitive threats
22.2.7 TWIST BIOSCIENCE
22.2.7.1 Business overview
22.2.7.2 Products offered
22.2.7.3 Recent developments
22.2.7.3.1 Product/Service launches
22.2.7.3.2 Deals
22.2.8 GENSCRIPT
22.2.8.1 Business overview
22.2.8.2 Products offered
22.2.8.3 Recent developments
22.2.8.3.1 Product/Service launches
22.2.8.3.2 Deals
22.2.8.3.3 Expansions
22.2.9 MARAVAI LIFESCIENCES
22.2.9.1 Business overview
22.2.9.2 Products offered
22.2.9.3 Recent developments
22.2.9.3.1 Product/Service launches
22.2.9.3.2 Deals
22.2.9.3.3 Expansions
22.2.9.4 MnM view
22.2.9.4.1 Key strengths
22.2.9.4.2 Strategic choices
22.2.9.4.3 Weaknesses & competitive threats
22.2.10 KANEKA CORPORATION
22.2.10.1 Business overview
22.2.10.2 Products offered
22.2.10.3 Recent developments
22.2.10.3.1 Expansions
22.2.11 AZENTA US INC.
22.2.11.1 Business overview
22.2.11.2 Products offered
22.2.11.3 Recent developments
22.2.11.3.1 Product/Service launches
22.2.11.3.2 Deals
22.2.12 OLIGOMAKER APS (PART OF TAG COPENHAGEN A/S)
22.2.12.1 Business overview
22.2.12.2 Products offered
22.2.13 BIOLEGIO B.V.
22.2.13.1 Business overview
22.2.13.2 Products offered
22.2.14 BIOLYTIC LAB PERFORMANCE, INC.
22.2.14.1 Business overview
22.2.14.2 Products offered
22.2.14.3 Recent developments
22.2.14.3.1 Product/Service launches
22.2.15 REVVITY (THROUGH SUBSIDIARY HORIZON DISCOVERY LTD.)
22.2.15.1 Business overview
22.2.15.2 Products offered
22.2.15.3 Recent developments
22.2.15.3.1 Product/Service launches
22.2.16 BIO-SYNTHESIS, INC.
22.2.16.1 Business overview
22.2.16.2 Products offered
22.2.17 CREATIVE BIOGENE
22.2.17.1 Business overview
22.2.17.2 Products offered
22.2.18 REPROCELL INC. (THROUGH SUBSIDIARY BIOSERVE)
22.2.18.1 Business overview
22.2.18.2 Products offered
22.2.19 BIOCOMMA LIMITED
22.2.19.1 Business overview
22.2.19.2 Products offered
23 RESEARCH METHODOLOGY
23.1 RESEARCH DATA
23.1.1 SECONDARY DATA
23.1.1.1 Key secondary sources
23.1.1.2 Key data from secondary research
23.1.2 PRIMARY DATA
23.1.2.1 Key primary participants
23.1.2.2 Breakdown of primary interviews
23.1.2.3 Key data from primary sources
23.2 MARKET SIZE ESTIMATION
23.2.1 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET ESTIMATION, 2025
23.2.1.1 Approach 1: Company revenue analysis-based estimation (bottom-up)
23.2.1.2 Approach 2: Secondary research
23.2.1.3 Approach 3: Primary research
23.2.1.4 Key industry insights
23.2.1.5 Approach 3: MnM repository analysis
23.2.2 SEGMENTAL MARKET SIZE ESTIMATION, 2025
23.3 MARKET GROWTH RATE PROJECTIONS
23.4 DATA TRIANGULATION
23.5 RESEARCH ASSUMPTIONS
23.6 RESEARCH LIMITATIONS & RISK ASSESSMENT
24 APPENDIX
24.1 DISCUSSION GUIDE
24.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
24.3 CUSTOMIZATION OPTIONS
24.4 RELATED REPORTS
24.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 OLIGONUCLEOTIDE SYNTHESIS MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2 OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS
TABLE 3 OLIGONUCLEOTIDE-BASED DRUGS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 4 SYNTHESIZED OLIGONUCLEOTIDES & OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 5 OLIGONUCLEOTIDE SYNTHESIS MARKET: ROLE IN ECOSYSTEM
TABLE 6 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGOS, BY KEY PLAYER, 2023–2025
TABLE 7 AVERAGE SELLING PRICE TREND FOR OLIGONUCLEOTIDE-BASED DRUGS, BY KEY PLAYER, 2023–2025
TABLE 8 AVERAGE SELLING PRICE OF OLIGONUCLEOTIDE SYNTHESIZERS, BY REGION, 2025
TABLE 9 OLIGONUCLEOTIDE SYNTHESIS MARKET: KEY CONFERENCES & EVENTS, 2026–2027
TABLE 10 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 11 CASE STUDIES OF AI IMPLEMENTATION IN OLIGONUCLEOTIDE SYNTHESIS MARKETCASE STUDIES OF AI IMPLEMENTATION IN THE OLIGONUCLEOTIDE SYNTHESIS MARKET
TABLE 12 CLIENT’S READINESS TO ADOPT GENERATIVE AI IN OLIGONUCLEOTIDE SYNTHESIS MARKET
TABLE 13 OLIGONUCLEOTIDE SYNTHESIS MARKET: INDICATIVE LIST OF PATENTS, 2025
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 REIMBURSEMENT SCENARIO FOR MAJOR COMMERCIAL OLIGONUCLEOTIDE THERAPEUTICS
TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%)
TABLE 21 KEY BUYING CRITERIA, BY END USER
TABLE 22 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 23 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 24 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 25 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 26 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 27 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 28 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 29 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 30 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY PRODUCT, 2024–2031 (VIALS/PREFILLED SYRINGES)
TABLE 31 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 32 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 33 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 34 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 35 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 37 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 39 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 41 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 44 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 46 APPROVED ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS
TABLE 47 ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 48 NORTH AMERICA: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49 EUROPE: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50 ASIA PACIFIC: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51 LATIN AMERICA: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52 MIDDLE EAST: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 53 GCC COUNTRIES: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54 APPROVED SIRNA OLIGONUCLEOTIDE-BASED DRUGS
TABLE 55 SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 56 NORTH AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57 EUROPE: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 58 ASIA PACIFIC: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59 LATIN AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 60 MIDDLE EAST: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 61 GCC COUNTRIES: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62 OTHER APPROVED OLIGONUCLEOTIDE-BASED DRUGS
TABLE 63 OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 64 NORTH AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65 EUROPE: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66 ASIA PACIFIC: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 67 LATIN AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68 MIDDLE EAST: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 69 GCC COUNTRIES: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 71 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 72 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 74 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 76 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 77 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 78 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 79 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 84 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 85 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 86 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 90 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 91 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2024–2031 (USD MILLION)
TABLE 93 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 95 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 97 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 98 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 99 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 101 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 103 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY REGION, 2024–2031 (USD MILLION)
TABLE 105 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 106 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY REGION, 2024–2031 (USD MILLION)
TABLE 110 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY REGION, 2024–2031 (USD MILLION)
TABLE 112 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 115 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 116 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY REGION, 2024–2031 (USD MILLION)
TABLE 117 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 119 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 120 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 121 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 124 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
TABLE 126 PRIMERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 127 NORTH AMERICA: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 128 EUROPE: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129 ASIA PACIFIC: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130 LATIN AMERICA: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 131 MIDDLE EAST: PRIMERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 132 GCC COUNTRIES: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 133 PROBES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 134 NORTH AMERICA: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135 EUROPE: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 ASIA PACIFIC: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137 LATIN AMERICA: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 138 MIDDLE EAST: PROBES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 139 GCC COUNTRIES: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 140 DNA OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 141 NORTH AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 142 EUROPE: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 143 ASIA PACIFIC: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 144 LATIN AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 145 MIDDLE EAST: DNA OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 146 GCC COUNTRIES: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 147 RNA OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 148 NORTH AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 149 EUROPE: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 150 ASIA PACIFIC: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 151 LATIN AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152 MIDDLE EAST: RNA OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 153 GCC COUNTRIES: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 154 OTHER OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 155 NORTH AMERICA: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 156 EUROPE: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 157 ASIA PACIFIC: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 158 LATIN AMERICA: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 159 MIDDLE EAST: OTHER OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 160 GCC COUNTRIES: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 161 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 162 CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 163 NORTH AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 164 EUROPE: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165 ASIA PACIFIC: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 166 LATIN AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167 MIDDLE EAST: CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 168 GCC COUNTRIES: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169 PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 170 NORTH AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 171 EUROPE: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 ASIA PACIFIC: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 173 LATIN AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 174 MIDDLE EAST: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 175 GCC COUNTRIES: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 177 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 178 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 179 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 180 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 181 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 183 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 185 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 186 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 187 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 191 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 192 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 193 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 196 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 197 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 198 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 199 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 200 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 201 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 202 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 203 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 205 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAEPUTIC DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 207 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAEPUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 208 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 209 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 210 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 212 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 213 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 214 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 215 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 216 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 217 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 218 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 219 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 220 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 221 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 222 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 223 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 224 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 225 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 226 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 227 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 228 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION)
TABLE 229 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 230 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 231 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 232 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 233 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION)
TABLE 234 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 235 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 236 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 237 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 238 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 239 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 240 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 241 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 242 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 243 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 244 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 245 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 246 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 247 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 248 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 249 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 250 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 251 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 252 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 253 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 254 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 255 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 256 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 257 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 258 OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 259 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 260 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 261 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 262 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 263 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 264 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 265 OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 266 PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 267 NORTH AMERICA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 268 EUROPE: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 269 ASIA PACIFIC: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 270 LATIN AMERICA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 271 MIDDLE EAST: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 272 GCC COUNTRIES: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 273 PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 274 DNA PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 275 NORTH AMERICA: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 276 EUROPE: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 277 ASIA PACIFIC: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 278 LATIN AMERICA: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 279 MIDDLE EAST: DNA PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 280 GCC COUNTRIES: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 281 RNA PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 282 NORTH AMERICA: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 283 EUROPE: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 284 ASIA PACIFIC: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 285 LATIN AMERICA: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 286 MIDDLE EAST: RNA PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 287 GCC COUNTRIES: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 288 MODIFIED PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 289 NORTH AMERICA: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 290 EUROPE: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 291 ASIA PACIFIC: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 292 LATIN AMERICA: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 293 MIDDLE EAST: MODIFIED PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 294 GCC COUNTRIES: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 295 ACTIVATORS/COUPLING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 296 NORTH AMERICA: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 297 EUROPE: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 298 ASIA PACIFIC: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 299 LATIN AMERICA: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 300 MIDDLE EAST: ACTIVATORS/COUPLING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 301 GCC COUNTRIES: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 302 DEPROTECTION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 303 NORTH AMERICA: DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 304 EUROPE: DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 305 ASIA PACIFIC: DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 306 LATIN AMERICA: DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 307 MIDDLE EAST: DEPROTECTION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 1 OLIGONUCLEOTIDE SYNTHESIS MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2 OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS
TABLE 3 OLIGONUCLEOTIDE-BASED DRUGS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 4 SYNTHESIZED OLIGONUCLEOTIDES & OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 5 OLIGONUCLEOTIDE SYNTHESIS MARKET: ROLE IN ECOSYSTEM
TABLE 6 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGOS, BY KEY PLAYER, 2023–2025
TABLE 7 AVERAGE SELLING PRICE TREND FOR OLIGONUCLEOTIDE-BASED DRUGS, BY KEY PLAYER, 2023–2025
TABLE 8 AVERAGE SELLING PRICE OF OLIGONUCLEOTIDE SYNTHESIZERS, BY REGION, 2025
TABLE 9 OLIGONUCLEOTIDE SYNTHESIS MARKET: KEY CONFERENCES & EVENTS, 2026–2027
TABLE 10 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 11 CASE STUDIES OF AI IMPLEMENTATION IN OLIGONUCLEOTIDE SYNTHESIS MARKETCASE STUDIES OF AI IMPLEMENTATION IN THE OLIGONUCLEOTIDE SYNTHESIS MARKET
TABLE 12 CLIENT’S READINESS TO ADOPT GENERATIVE AI IN OLIGONUCLEOTIDE SYNTHESIS MARKET
TABLE 13 OLIGONUCLEOTIDE SYNTHESIS MARKET: INDICATIVE LIST OF PATENTS, 2025
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 REIMBURSEMENT SCENARIO FOR MAJOR COMMERCIAL OLIGONUCLEOTIDE THERAPEUTICS
TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%)
TABLE 21 KEY BUYING CRITERIA, BY END USER
TABLE 22 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 23 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 24 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 25 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 26 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 27 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 28 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 29 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 30 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY PRODUCT, 2024–2031 (VIALS/PREFILLED SYRINGES)
TABLE 31 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 32 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 33 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 34 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 35 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 37 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 39 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 41 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 44 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 46 APPROVED ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS
TABLE 47 ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 48 NORTH AMERICA: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49 EUROPE: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50 ASIA PACIFIC: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51 LATIN AMERICA: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52 MIDDLE EAST: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 53 GCC COUNTRIES: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54 APPROVED SIRNA OLIGONUCLEOTIDE-BASED DRUGS
TABLE 55 SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 56 NORTH AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57 EUROPE: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 58 ASIA PACIFIC: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59 LATIN AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 60 MIDDLE EAST: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 61 GCC COUNTRIES: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62 OTHER APPROVED OLIGONUCLEOTIDE-BASED DRUGS
TABLE 63 OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 64 NORTH AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65 EUROPE: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66 ASIA PACIFIC: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 67 LATIN AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68 MIDDLE EAST: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 69 GCC COUNTRIES: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 71 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 72 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 74 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 76 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 77 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 78 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 79 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 84 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 85 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 86 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 90 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 91 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2024–2031 (USD MILLION)
TABLE 93 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 95 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 97 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 98 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 99 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 101 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 103 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY REGION, 2024–2031 (USD MILLION)
TABLE 105 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 106 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY REGION, 2024–2031 (USD MILLION)
TABLE 110 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY REGION, 2024–2031 (USD MILLION)
TABLE 112 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 115 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 116 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY REGION, 2024–2031 (USD MILLION)
TABLE 117 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 119 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 120 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 121 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 124 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION)
TABLE 126 PRIMERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 127 NORTH AMERICA: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 128 EUROPE: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129 ASIA PACIFIC: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130 LATIN AMERICA: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 131 MIDDLE EAST: PRIMERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 132 GCC COUNTRIES: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 133 PROBES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 134 NORTH AMERICA: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135 EUROPE: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 ASIA PACIFIC: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137 LATIN AMERICA: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 138 MIDDLE EAST: PROBES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 139 GCC COUNTRIES: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 140 DNA OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 141 NORTH AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 142 EUROPE: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 143 ASIA PACIFIC: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 144 LATIN AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 145 MIDDLE EAST: DNA OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 146 GCC COUNTRIES: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 147 RNA OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 148 NORTH AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 149 EUROPE: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 150 ASIA PACIFIC: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 151 LATIN AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152 MIDDLE EAST: RNA OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 153 GCC COUNTRIES: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 154 OTHER OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 155 NORTH AMERICA: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 156 EUROPE: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 157 ASIA PACIFIC: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 158 LATIN AMERICA: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 159 MIDDLE EAST: OTHER OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 160 GCC COUNTRIES: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 161 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 162 CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 163 NORTH AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 164 EUROPE: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165 ASIA PACIFIC: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 166 LATIN AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167 MIDDLE EAST: CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 168 GCC COUNTRIES: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169 PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 170 NORTH AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 171 EUROPE: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 ASIA PACIFIC: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 173 LATIN AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 174 MIDDLE EAST: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 175 GCC COUNTRIES: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 177 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 178 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 179 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 180 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 181 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 183 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 185 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 186 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 187 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 191 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 192 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 193 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 196 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 197 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 198 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 199 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 200 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 201 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 202 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 203 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 205 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAEPUTIC DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 207 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAEPUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 208 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 209 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 210 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 212 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 213 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 214 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 215 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 216 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 217 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 218 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 219 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 220 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 221 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 222 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 223 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 224 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 225 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 226 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 227 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 228 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION)
TABLE 229 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 230 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 231 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 232 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 233 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION)
TABLE 234 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 235 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 236 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 237 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 238 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 239 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 240 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 241 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 242 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 243 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 244 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 245 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 246 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 247 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 248 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 249 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 250 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 251 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 252 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 253 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 254 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 255 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 256 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 257 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 258 OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 259 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 260 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 261 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 262 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 263 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 264 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 265 OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 266 PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 267 NORTH AMERICA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 268 EUROPE: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 269 ASIA PACIFIC: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 270 LATIN AMERICA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 271 MIDDLE EAST: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 272 GCC COUNTRIES: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 273 PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 274 DNA PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 275 NORTH AMERICA: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 276 EUROPE: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 277 ASIA PACIFIC: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 278 LATIN AMERICA: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 279 MIDDLE EAST: DNA PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 280 GCC COUNTRIES: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 281 RNA PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 282 NORTH AMERICA: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 283 EUROPE: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 284 ASIA PACIFIC: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 285 LATIN AMERICA: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 286 MIDDLE EAST: RNA PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 287 GCC COUNTRIES: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 288 MODIFIED PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 289 NORTH AMERICA: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 290 EUROPE: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 291 ASIA PACIFIC: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 292 LATIN AMERICA: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 293 MIDDLE EAST: MODIFIED PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 294 GCC COUNTRIES: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 295 ACTIVATORS/COUPLING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 296 NORTH AMERICA: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 297 EUROPE: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 298 ASIA PACIFIC: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 299 LATIN AMERICA: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 300 MIDDLE EAST: ACTIVATORS/COUPLING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 301 GCC COUNTRIES: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 302 DEPROTECTION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 303 NORTH AMERICA: DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 304 EUROPE: DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 305 ASIA PACIFIC: DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 306 LATIN AMERICA: DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 307 MIDDLE EAST: DEPROTECTION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
In the coming five years, growth in the oligonucleotide synthesis market is likely to be centered on China, Malaysia, Singapore, and India. This can be attributed to the growing availability of synthesized oligos along with an increase in the R&D funding and activities in the APAC region. Furthermore, increasing focus of prominent players in the APAC market is another factor driving the growth of this market. For instance, in July 2013, Integrated DNA Technologies, Inc. (IDT) opened an oligonucleotides manufacturing facility in Singapore to cater to the research companies in the APAC region, thereby establishing its footprint in the APAC market. Such developments are likely to spur the growth of the APAC oligonucleotide synthesis market in the coming years.
The key strategies followed by most companies in the oligonucleotide synthesis market are new product launches; agreements, collaborations, and partnerships; mergers and acquisitions; and expansions. Of all the growth strategies adopted by players in this field, agreements, collaborations, and partnerships accounted for the largest share of XX% of the overall growth strategies from 2010 to 2014. Some leading players adopting these strategies are BioAutomation Corporation (U.S.), Eurofins Genomics (Germany), and GE Healthcare (U.K.). Expansions accounted for the second-largest share of XX% of the overall growth strategies adopted by the players in the market.
The prominent players in the oligonucleotide synthesis market are Agilent Technologies, Inc. (U.S.), BioAutomation Corporation (U.S.), BioSearch Technologies, Inc. (U.S.), Eurofins Genomics (Germany), Eurogentec (Belgium), GE Healthcare (U.K.), Glen Research (U.S.), Gene Link, Inc. (U.S.), GenScript USA Inc. (U.S.), GeneDesign, Inc. (Japan), Integrated DNA Technologies, Inc. (IDT) (U.S.), Link Technologies, Ltd. (U.K.), Nitto Denko Avecia, Inc. (U.S.), Sigma-Aldrich Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), and TriLink BioTechnologies, Inc. (U.S.).
North America commands the largest share of the global oligonucleotide synthesis market, followed by Europe. However, the European oligonucleotide synthesis market is expected to grow at a slower pace as compared to North America due to the Eurozone debt crisis. The Asia-Pacific market, on the other hand, is in the growth phase and is the fastest-growing region in the global oligonucleotide synthesis market. The growth in the APAC oligonucleotide synthesis market is likely to be centered at China, Malaysia, Singapore, and India. This can be attributed to the growing availability of synthesized oligos and the increase in R&D funding and activities in the APAC region. Furthermore, increasing focus of prominent players on the APAC region is another factor driving the growth of this market.
Oligonucleotide synthesis is a highly commoditized market. With its rising attractiveness, an increasing number of companies are moving into this niche market, resulting in price pressure. Oligos have been branded as relatively more expensive research tools as compared to other life sciences research tools. This is further restricting the industry growth, as there are certain limitations related to increasing the cost of oligos. This factor is making it difficult for market players to survive and/or grow at a faster and desired pace. However, market consolidation in the coming years can bring price enhancement in this industry.
The importance of synthetic oligonucleotides as therapeutic drugs for treating diseases has grown significantly over the last decade. Some of the major driving factors for this growth are characterization of more targets following the identification of the human genome, advancements in antisense oligonucleotides, and the development of double stranded small interfering RNA (siRNA). Therapeutic oligos can either be single stranded such as antisense oligonucleotides or double stranded such as siRNA. Furthermore, therapeutic oligos can be useful in treating diseases ranging from viral infections, respiratory diseases, and cancer to rare diseases such as Duchenne Muscular Dystrophy (DMD), Cystic Fibrosis, and Thrombic Thrombocytopenic Purpura.
Currently, only two oligonucleotide-based drugs, namely, Vitravene and Macugen have received market approval and a large number of oligonucleotide-based drugs are in various stages of clinical development in the U.S., Canada, Europe, and other parts of the world. As of 2011, there were over XX oligonucleotide-based drugs in clinical development in the U.S., Europe, and Canada; some of these include antisense oligonucleotides, immunostimulatory oligonucleotides, DNA duplex decoys, siRNAs, ribozymes, microRNAs, aptamers, and spiegelmers. Although most oligonucleotides in clinical development are chemically similar, the mechanisms of their action vary widely. As a result, the development of a unified set of regulatory guidelines that can effectively address the safety and quality requirements for such a diverse group of molecular entities with various unique mechanisms of action is a challenging task.
There are no formal regulatory guidelines available from any regulatory agency for the development of this class of therapeutics. It has been a general practice for regulatory agencies to apply guidelines proposed for small molecules to oligonucleotide therapeutics, owing to their similar characteristics. These include all quality-related regulatory guidelines issued by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Thus, there is a need to address the basic regulatory issues regarding the chemistry, manufacturing, and control of drugs and products belonging to this unique class of therapeutics.
More Publications
Protein Expression Market by Product (Instruments, Reagents, Kits, Consumables, Software, Services), System Type (Mammalian, Insect, Yeast), Workflow (Cloning, Translation, PTM), Scale, Protein Type, Application, Competition - Global Forecast to 2031
US$ 2,970.00
May 2026
749 pages
Cell-based Assays Market by Product & Service (Reagents, Microplate, Cell Lines, Assay Kits, Instrument & Software, Services), Application (Drug Discovery, Research), End User (CROs, Pharmaceutical Companies, Research Institutes) - Global Forecast to 2025
US$ 2,970.00
March 2021
231 pages
Population Health Management Market by Component (Software, Services), Functionality (Analytics, Care Management, Risk & Predictive Analytics, VBC), End User (Hospital, Clinic, Payer, Public Health, Employer), Organization Size - Global Forecast to 2031
US$ 1,782.00
July 2026
335 pages
